American College of Cardiology Aug 30 2024 Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19 related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC , the flagship journal of the American College of Cardiology. The research will be simultaneously published with presentations at the

Tag-uri: Coronavirus